173 related articles for article (PubMed ID: 33029249)
1. UPDATES IN AGGRESSIVE PITUITARY TUMORS.
Burcea I; Poiana C
Acta Endocrinol (Buchar); 2020; 16(2):267-273. PubMed ID: 33029249
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of prognostic utility of Ki-67, P53, and O-6-methylguanine-DNA methyltransferase expression in pituitary tumors.
Das C; Mondal P; Mukhopadhyay M; Mukhopadhyay S; Ghosh I; Handral A
J Lab Physicians; 2019; 11(4):323-329. PubMed ID: 31929698
[TBL] [Abstract][Full Text] [Related]
3. The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas.
Hasanov R; Aydoğan Bİ; Kiremitçi S; Erden E; Güllü S
Endocr Pathol; 2019 Mar; 30(1):49-55. PubMed ID: 30610566
[TBL] [Abstract][Full Text] [Related]
4. Aggressive pituitary tumors.
Chatzellis E; Alexandraki KI; Androulakis II; Kaltsas G
Neuroendocrinology; 2015; 101(2):87-104. PubMed ID: 25571935
[TBL] [Abstract][Full Text] [Related]
5. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.
Thapar K; Scheithauer BW; Kovacs K; Pernicone PJ; Laws ER
Neurosurgery; 1996 Apr; 38(4):765-70; discussion 770-1. PubMed ID: 8692397
[TBL] [Abstract][Full Text] [Related]
6. Refractory pituitary adenoma: a novel classification for pituitary tumors.
Dai C; Feng M; Liu X; Ma S; Sun B; Bao X; Yao Y; Deng K; Wang Y; Xing B; Lian W; Zhong D; Ma W; Wang R
Oncotarget; 2016 Dec; 7(50):83657-83668. PubMed ID: 27845901
[TBL] [Abstract][Full Text] [Related]
7. Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review.
Dai C; Liang S; Sun B; Li Y; Kang J
Front Oncol; 2021; 11():773905. PubMed ID: 34869016
[TBL] [Abstract][Full Text] [Related]
8. Clinically aggressive phenotype: A clinicopathological case series of atypical pituitary adenomas.
Lv L; Hu Y; Yin S; Wang M; Zhou P; Zhang N; Ma W; Zhang S; Jiang S
Clin Neurol Neurosurg; 2018 Apr; 167():93-98. PubMed ID: 29471288
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Invasion, Markers of Proliferation, and Classification of Giant Pituitary Tumors, in a Georeferred Cohort in Brazil of 50 Patients, with a Long-Term Postoperative Follow-Up.
Zakir JC; Casulari LA; Rosa JW; Rosa JW; de Mello PA; de Magalhães AV; Naves LA
Int J Endocrinol; 2016; 2016():7964523. PubMed ID: 27635138
[TBL] [Abstract][Full Text] [Related]
10. Cytohistological correlation in pituitary tumor and immunological assessment with the help of Ki-67.
Sen A; Das C; Mukhopadhyay M; Mukhopadhyay S; Deb S; Mukhopadhyay B
J Postgrad Med; 2017; 63(2):96-99. PubMed ID: 27779153
[TBL] [Abstract][Full Text] [Related]
11. Early recognition of aggressive pituitary adenomas: a single-centre experience.
Ceccato F; Regazzo D; Barbot M; Denaro L; Emanuelli E; Borsetto D; Rolma G; Alessio L; Gardiman MP; Lombardi G; Albiger N; D'Avella D; Scaroni C
Acta Neurochir (Wien); 2018 Jan; 160(1):49-55. PubMed ID: 29170844
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
Raverot G; Sturm N; de Fraipont F; Muller M; Salenave S; Caron P; Chabre O; Chanson P; Cortet-Rudelli C; Assaker R; Dufour H; Gaillard S; François P; Jouanneau E; Passagia JG; Bernier M; Cornélius A; Figarella-Branger D; Trouillas J; Borson-Chazot F; Brue T
J Clin Endocrinol Metab; 2010 Oct; 95(10):4592-9. PubMed ID: 20660056
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P
J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794
[TBL] [Abstract][Full Text] [Related]
14. New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors.
Nishioka H; Inoshita N
Brain Tumor Pathol; 2018 Apr; 35(2):57-61. PubMed ID: 29318396
[TBL] [Abstract][Full Text] [Related]
15. A classification tree approach for pituitary adenomas.
Righi A; Agati P; Sisto A; Frank G; Faustini-Fustini M; Agati R; Mazzatenta D; Farnedi A; Menetti F; Marucci G; Foschini MP
Hum Pathol; 2012 Oct; 43(10):1627-37. PubMed ID: 22446019
[TBL] [Abstract][Full Text] [Related]
16. Classification and pathology of pituitary tumors.
Kontogeorgos G
Endocrine; 2005 Oct; 28(1):27-35. PubMed ID: 16311407
[TBL] [Abstract][Full Text] [Related]
17. Ki-67 and p53 immunostaining assessment of proliferative activity in salivary tumors.
Faur AC; Sas I; Motoc AG; Cornianu M; Zamfir CL; Lazăr DC; Folescu R
Rom J Morphol Embryol; 2015; 56(4):1429-39. PubMed ID: 26743291
[TBL] [Abstract][Full Text] [Related]
18. [Pituitary carcinomas and aggressive adenomas: an overview and new therapeutic options].
Maïza JC; Caron P
Ann Endocrinol (Paris); 2009 Sep; 70 Suppl 1():S12-9. PubMed ID: 19878763
[TBL] [Abstract][Full Text] [Related]
19. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary.
Lopes MBS
Acta Neuropathol; 2017 Oct; 134(4):521-535. PubMed ID: 28821944
[TBL] [Abstract][Full Text] [Related]
20. Ki-67 in pituitary neoplasms: a review--part I.
Salehi F; Agur A; Scheithauer BW; Kovacs K; Lloyd RV; Cusimano M
Neurosurgery; 2009 Sep; 65(3):429-37; discussion 437. PubMed ID: 19687686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
